OREANDA-NEWS. May 21, 2015. Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests, announces the launch of a new cloud based cognitive assessment product to accelerate development of Alzheimer's disease treatments, Cantab Connect Alzheimer's.

The global market for Alzheimer's disease treatment is expected to more than double in value from \\$4.9 billion in 2013 to reach an estimated \\$13.3 billion by 2023, making the race to develop disease-modifying therapies big business for the pharmaceutical industry. In order to achieve this, more sensitive analytical tools are required to identify drugs that can alter the course of the disease. The Cantab Connect Alzheimer's cognitive assessment product provides sensitive measures that are far more effective than traditional paper-based tests, enabling pharmaceutical companies to increase the chances of identifying new drugs that have positive effects on Alzheimer's patients and gaining subsequent regulatory and market approval.

The market size of cognitive assessments in Alzheimer's disease trials is estimated to be in excess of \\$17m. With over thirty Alzheimer's trials already completed using proprietary Cambridge Cognition products, the Company forecast this to be an increasing area of growth potential following the launch of Cantab Connect Alzheimer's.

Nick Kerton, Chief Executive Officer of Cambridge Cognition Holdings plc commented: "Cambridge Cognition has become synonymous with innovation in healthcare, research and development for Alzheimer's. Today we launch the first in a series of cognitive assessment software products to support effective development of new drugs across a range of disease areas. With the capabilities of our cloud technology combined with acutely sensitive measures of brain function, pharmaceutical companies can now conduct large, objective and reliable studies in clinical development to combat the disease quicker."